Literature DB >> 28595171

Serum Irisin Predicts Mortality Risk in Acute Heart Failure Patients.

Shutong Shen1, Rongrong Gao1, Yihua Bei2, Jin Li2, Haifeng Zhang1, Yanli Zhou1, Wenming Yao1, Dongjie Xu1, Fang Zhou1, Mengchao Jin1, Siqi Wei1, Kai Wang1, Xuejuan Xu1, Yongqin Li2, Junjie Xiao2, Xinli Li1.   

Abstract

BACKGROUND/AIMS: Irisin is a peptide hormone cleaved from a plasma membrane protein fibronectin type III domain containing protein 5 (FNDC5). Emerging studies have indicated association between serum irisin and many major chronic diseases including cardiovascular diseases. However, the role of serum irisin as a predictor for mortality risk in acute heart failure (AHF) patients is not clear.
METHODS: AHF patients were enrolled and serum was collected at the admission and all patients were followed up for 1 year. Enzyme-linked immunosorbent assay was used to measure serum irisin levels. To explore predictors for AHF mortality, the univariate and multivariate logistic regression analysis, and receiver-operator characteristic (ROC) curve analysis were used. To determine the role of serum irisin levels in predicting survival, Kaplan-Meier survival analysis was used.
RESULTS: In this study, 161 AHF patients were enrolled and serum irisin level was found to be significantly higher in patients deceased in 1-year follow-up. The univariate logistic regression analysis identified 18 variables associated with all-cause mortality in AHF patients, while the multivariate logistic regression analysis identified 2 variables namely blood urea nitrogen and serum irisin. ROC curve analysis indicated that blood urea nitrogen and the most commonly used biomarker, NT-pro-BNP, displayed poor prognostic value for AHF (AUCs ≤ 0.700) compared to serum irisin (AUC = 0.753). Kaplan-Meier survival analysis demonstrated that AHF patients with higher serum irisin had significantly higher mortality (P<0.001).
CONCLUSION: Collectively, our study identified serum irisin as a predictive biomarker for 1-year all-cause mortality in AHF patients though large multicenter studies are highly needed.
© 2017 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Acute heart failure; Biomarker; Irisin; Prognosis

Mesh:

Substances:

Year:  2017        PMID: 28595171     DOI: 10.1159/000477867

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  15 in total

Review 1.  The role of Irisin in multiorgan protection.

Authors:  Jun Ma; Ken Chen
Journal:  Mol Biol Rep       Date:  2021-01-03       Impact factor: 2.316

2.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

3.  Decreased Concentration of Irisin Is Associated with Poor Functional Outcome in Ischemic Stroke.

Authors:  Wen-Jun Tu; Han-Cheng Qiu; Jian-Lei Cao; Qiang Liu; Xian-Wei Zeng; Ji-Zong Zhao
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 4.  Irisin: linking metabolism with heart failure.

Authors:  Jiamin Li; Susu Xie; Lei Guo; Jun Jiang; Han Chen
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

5.  Correlates and Consequences of High Serum Irisin Concentration in Patients on Hemodialysis: A Longitudinal Analysis.

Authors:  Janet M Chiang; Cynthia Delgado; George A Kaysen; Mark R Segal; Glenn M Chertow; Kirsten L Johansen
Journal:  J Ren Nutr       Date:  2020-11-28       Impact factor: 4.354

6.  Adropin and Irisin in Patients with Cardiac Cachexia.

Authors:  Ali Kemal Kalkan; Huseyin Altug Cakmak; Mehmet Erturk; Kübra Erol Kalkan; Fatih Uzun; Omer Tasbulak; Vesile Ornek Diker; Suleyman Aydin; Ahmet Celik
Journal:  Arq Bras Cardiol       Date:  2018-07-02       Impact factor: 2.000

7.  A pilot study on the relation between irisin single-nucleotide polymorphism and risk of myocardial infarction.

Authors:  Eman Ae Badr; Rasha G Mostafa; Samah M Awad; Hala Marwan; Hamed M Abd El-Bary; Hossam Em Shehab; Samar Ebrahim Ghanem
Journal:  Biochem Biophys Rep       Date:  2020-02-21

Review 8.  Irisin: A Promising Target for Ischemia-Reperfusion Injury Therapy.

Authors:  Yani Wang; Huibin Liu; Na Sun; Jing Li; Xiang Peng; Ying Jia; Jason Karch; Bo Yu; Xander H T Wehrens; Jinwei Tian
Journal:  Oxid Med Cell Longev       Date:  2021-10-29       Impact factor: 6.543

9.  Exercise-Induced Circulating Irisin Level Is Correlated with Improved Cardiac Function in Rats.

Authors:  Dae Yun Seo; Jun Hyun Bae; Tae Nyun Kim; Hyo-Bum Kwak; Pham Trong Kha; Jin Han
Journal:  Int J Environ Res Public Health       Date:  2020-05-29       Impact factor: 3.390

10.  Cardiometabolic Effects of Irisin in Patients with End-Stage Renal Disease on Regular Hemo- or Peritoneal Dialysis.

Authors:  Botond Csiky; Balázs Sági; Vanessza Emmert; István Wittmann; Endre Sulyok
Journal:  Blood Purif       Date:  2021-08-02       Impact factor: 3.348

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.